Skip to content

evaluation of safety, dosage and efficacy of fentanyl in neonates and children of age 6 years old and younger -uncontrolled, open label study-

evaluation of safety, dosage and efficacy of fentanyl in neonates and children of age 6 years old and younger -uncontrolled, open label study- - IISPedAne001

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1091220006
Enrollment
120
Registered
2006-03-08
Start date
2005-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who require administration of narcotic analgesia during general anesthesia for operation or procedures. Patients must be intubated, under respiratory care and receiving general anesthesia. Patients who is receiving epidural anesthetics must be excluded.

Interventions

Intervention type:DRUG Name of intervention:Fentanyl Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Freque

Sponsors

National Center for Child Health and Development
Lead Sponsor
Research Institute, Osaka Medical Center and Research Institute for Maternal and Child Health Kitasato University Hospital Kobe University Hospital National Center for Child Health and Development The University of Tokyo Hospital National Hospital Organization Okayama Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who require administration of narcotic analgesia during surgery/procedures. Patients must be hospitalized, intubated, vetilated and receiving general anesthesia. 2) 6 years old or younger. 3) Written informed consent from legal representative.

Exclusion criteria

Exclusion criteria: 1) outpatients 2) patients who receive epidural anesthetics. 3) patients who have been intubated before surgery. 4) patients who received nalcotic analgesia before surgery. 5) patients with unstable circulatory status because of congenital cardiac anomaly, diaphragmatic hernia, and so on. 6) patients with severely impaired hepatic or renal function. 7) patients who have history of serious drug allergy. 8) Patients who have taken or is taking ritonavir.

Design outcomes

Primary

MeasureTime frame
Efficacy evaluated by physicians' clinical observation. % increase of systolic blood pressure and heart rate within 20 min after first invasive surgical procedure should be considered for physicians' decision-making.

Secondary

MeasureTime frame
Evaluation based on % increase of systolic blood pressure, and heart rate within 20min after first invasive surgical procedure.

Countries

Japan

Contacts

Public ContactKuriyama Takeshi

National Center for Child Health and Development

kuriyama-t@ncchd.go.jp+81-3-5494-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026